GSTM1

GSTM1 is a class-mu cytosolic glutathione S-transferase that conjugates electrophilic substrates—including carcinogens such as styrene oxide and hydroquinone, and reactive oxygen species derived from pollutants—with glutathione, thereby protecting cells from genotoxic damage and oxidant-driven inflammation (PMID:3864155, PMID:11424177, PMID:15141365, PMID:14726165). Independent of its catalytic activity, GSTM1 directly binds apoptosis signal-regulating kinase 1 (ASK1) through its C-terminal domain, suppressing ASK1 oligomerization and kinase activity to inhibit stress-induced apoptosis (PMID:11278289, PMID:30989213). The common GSTM1-null allele, generated by homozygous deletion via unequal crossing-over within the tandem gene cluster at chromosome 1p13.3, eliminates both enzymatic and ASK1-inhibitory functions; GSTM1 transcription is further modulated by AP-2α binding at a functional promoter polymorphism and by promoter CpG methylation (PMID:3174634, PMID:8317488, PMID:19228880, PMID:30989213). GSTM1-null individuals exhibit heightened susceptibility to pollutant-augmented allergic inflammation and increased genotoxic damage, consistent with loss of both detoxification and anti-apoptotic protective mechanisms (PMID:14726165, PMID:15141365).

1. 1985 High

   Identification of GSTM1 as a distinct enzyme class (mu) among cytosolic glutathione transferases established the foundational biochemical classification and substrate specificity framework for the gene family.

   Evidence Amino-terminal sequencing, substrate specificity profiling, inhibitor sensitivity panels, and immunoprecipitation across rat, mouse, and human tissues

   PMID:3864155

   Open questions at the time

   • Catalytic mechanism at the active-site level not resolved
   • No structural model available at this point
   • Human isoform-specific functions not distinguished
2. 1988 High

   Demonstration that the GSTM1-null phenotype arises from a homozygous gene deletion—abolishing mRNA expression and enzyme activity—explained the polymorphic absence of mu-class GST activity in human populations and established the null genotype as a binary loss-of-function variant.

   Evidence Northern blotting, Southern blotting with class-mu cDNA probe, and enzyme activity assays in peripheral leukocytes

   PMID:3174634

   Open questions at the time

   • Precise molecular breakpoints of the deletion not mapped
   • Functional consequences beyond trans-stilbene oxide metabolism not yet tested
3. 1993 High

   Mapping all five GSTM genes to a tandem cluster at 1p13.3 and identifying near-identical 3′-UTR sequences between GSTM1 and GSTM2 provided a mechanistic explanation for null-allele generation through unequal crossing-over.

   Evidence Locus-specific PCR on somatic cell hybrids, Southern blot hybridization, and FISH with a YAC clone containing the full cluster

   PMID:8317488

   Open questions at the time

   • Exact recombination breakpoints not sequenced
   • Frequency of de novo deletion events unknown
4. 2001 High

   Discovery that GSTM1 physically binds and inhibits ASK1—suppressing its oligomerization, kinase activity, and downstream apoptosis independently of glutathione conjugation—revealed a catalysis-independent signalling function for GSTM1.

   Evidence Yeast two-hybrid screen, reciprocal co-immunoprecipitation, in vitro binding assay, domain-deletion mapping, kinase activity assay, and apoptosis assay in cultured cells (mouse GSTM1)

   PMID:11278289

   Open questions at the time

   • Structural basis of the GSTM1–ASK1 interface not determined
   • Relevance of ASK1 inhibition in human tissues under physiological conditions not tested
   • Whether other GST-mu family members share ASK1-inhibitory activity unclear
5. 2001 Medium

   Functional demonstration that GSTM1-positive human cells resist styrene oxide–induced cytotoxicity and mutagenicity directly linked GSTM1 enzymatic activity to protection against an occupational carcinogen.

   Evidence Dose-response cytotoxicity and HPRT mutation frequency assays in isogenic GSTM1-present versus GSTM1-null human cell lines

   PMID:11424177

   Open questions at the time

   • Single study; replication in additional cell types needed
   • In vivo dosimetry not established
6. 2004 High

   Evidence that GSTM1-null individuals show augmented allergic inflammation (higher IgE, histamine) upon diesel exhaust particle challenge, and greater hydroquinone-induced genotoxic damage, extended GSTM1's protective role from chemical carcinogen metabolism to pollutant-driven immune modulation and environmental genotoxicity.

   Evidence Randomised crossover nasal challenge study with diesel exhaust particles (human); ex vivo micronucleus assay in GSTM1-genotyped human lymphocytes treated with hydroquinone

   PMID:14726165 PMID:15141365

   Open questions at the time

   • Downstream mediators linking GSTM1-null status to enhanced IgE production not identified
   • Whether GSTM1 directly detoxifies diesel exhaust particle-derived ROS or acts indirectly not resolved
7. 2008 Medium

   Characterization of population-specific GSTM1 copy number variation showed that >75% of Caucasians carry the deletion while African populations retain higher copy numbers, highlighting the need to account for CNV rather than simple SNP-based genotyping in association studies.

   Evidence Novel CNV genotyping assay applied to HapMap CEU and YRI lymphoblastoid cell lines

   PMID:18948376

   Open questions at the time

   • Functional impact of carrying two versus one copy not directly measured
   • Broader global population survey of CNV not performed
8. 2009 High

   Identification of a functional promoter polymorphism that alters AP-2α transcription factor binding, reducing GSTM1 transcription and revealing a U-shaped gene-dosage effect on breast cancer risk, established that GSTM1 expression level—not just presence versus absence—is a critical determinant of its biological impact.

   Evidence Case-control genotyping (1920 subjects), meta-analysis of 41 studies, EMSA for AP-2α binding, luciferase reporter assay, and quantitative RT-PCR

   PMID:19228880

   Open questions at the time

   • Mechanism underlying the detrimental effect of very high GSTM1 expression not elucidated
   • Other transcription factors regulating GSTM1 beyond AP-2α and NRF2 not comprehensively surveyed
9. 2019 Medium

   Linking GSTM1 promoter hypomethylation to elevated expression in endometriosis, and showing that GSTM1 overexpression increases cell viability and suppresses apoptosis in endometrial epithelial cells, connected the ASK1-inhibitory function to a disease-relevant phenotype and identified epigenetic regulation as a physiological control mechanism.

   Evidence Pyrosequencing of promoter CpG methylation, RT-qPCR, immunohistochemistry, GSTM1 overexpression in primary endometrial cells, CCK-8 viability assay, and flow cytometry for apoptosis

   PMID:30989213

   Open questions at the time

   • Causal relationship between GSTM1 overexpression and endometriosis pathogenesis not established
   • Whether anti-apoptotic effect is mediated via ASK1 in this context not directly tested
   • No in vivo model used

• The structural basis of the GSTM1–ASK1 interaction, the precise mechanism by which high GSTM1 expression becomes detrimental, and the relative contributions of catalytic versus non-catalytic functions in specific disease contexts remain unresolved.
• No co-crystal or cryo-EM structure of the GSTM1–ASK1 complex
• Quantitative contribution of catalytic detoxification versus ASK1 inhibition to cancer or inflammatory protection not separated in vivo
• Comprehensive identification of additional non-catalytic binding partners not performed